International Oncology Network - Cancer & Hematology News

March 2010 Blog Posts (5)

Capecitabine in combination with oxaliplatin approved in Europe for the adjuvant treatment of patients with early colon cancer

A new treatment option will help more colon cancer patients in Europe to benefit from treatment with capecitabine (Xeloda; Roche), highly effective targeted oral chemotherapy uniquely activating cancer-killing agent 5-FU…

Continue

Added by Peter Hofland, PhD on March 30, 2010 at 6:30am — No Comments

Bendamustine Recommended for Approval in Europe for the Treatment of Hematological Malignancies

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending that marketing authorisations can be granted bendamustine HCI (Levcat, Mundipharma International, Cambridge, UK; also market as… Continue

Added by Peter Hofland, PhD on March 19, 2010 at 7:30am — No Comments

Dutch Diagnostic Company to Play Pivotal Role in ISPY-2 Trial for Breast Cancer

Netherlands genomics cancer diagnostics company, a world leader in molecular cancer diagnostics focused on the personalized medicine revolution striving to bring more effective, individualized treatments within reach of patients, will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.

I-SPY… Continue

Added by Peter Hofland, PhD on March 17, 2010 at 8:00am — No Comments

European Breast Cancer Patients to be Treated With Revolutionary Therapy System

For the first time, breast cancer patients in Europe will receive treatment using a revolutionary system called AccuBoost. The Italian hospital where the patients are being treated is using the technology to pinpoint the tumor bed and treat it whilst still protecting the patient's healthy surrounding tissue and…

Continue

Added by Peter Hofland, PhD on March 4, 2010 at 6:00am — No Comments

Updated IMPACT Results Confirm that Provenge® Improves Overall Survival in Patients with Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Data from the pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study, a 512-patient, multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC) with overall survival as the primary endpoint, demonstrates that sipuleucel-T…

Continue

Added by Peter Hofland, PhD on March 3, 2010 at 4:00pm — No Comments